Literature DB >> 16495763

Carvedilol inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension.

Hideki Fujio1, Kazufumi Nakamura, Hiromi Matsubara, Kengo Fukushima Kusano, Katsumasa Miyaji, Satoshi Nagase, Tetsuya Ikeda, Aiko Ogawa, Keiko Ohta-Ogo, Daiji Miura, Aya Miura, Masahiro Miyazaki, Hiroshi Date, Tohru Ohe.   

Abstract

Idiopathic pulmonary arterial hypertension (IPAH) is associated with proliferation of smooth muscle cells (SMCs) in small pulmonary arteries. Inhibition of proliferation of pulmonary artery smooth muscle cells (PASMCs) may be an effective treatment of patients with idiopathic pulmonary arterial hypertension. Recent studies have shown that carvedilol, an alpha- and beta-blocker with antioxidant and calcium channel blocking properties, inhibits the proliferation of cultured normal human pulmonary artery smooth muscle cells. In this study, we tested the hypothesis that carvedilol has antiproliferative effects on pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Pulmonary artery smooth muscle cells from six idiopathic pulmonary arterial hypertension patients who had undergone lung transplantation were cultured. To determine cell proliferation, H-thymidine incorporation was measured. Platelet-derived growth factor-induced proliferation of IPAH-PASMCs was significantly greater than that of normal control pulmonary artery smooth muscle cells. Carvedilol (0.1 microM to 10 microM) inhibited the proliferation of idiopathic pulmonary arterial hypertension-pulmonary artery smooth muscle cells in a concentration-dependent manner. Prazosin (an alpha-blocker) and N-acetyl L cysteine (an antioxidant agent) (0.1 microM to 10 microM) did not inhibit their proliferation, but the high concentration of propranolol (a beta-blocker) and nifedipine (a calcium channel blocker) (10 microM) inhibited the proliferation. The combination of propranolol and nifedipine inhibited the proliferation but only at a high concentration (10 microM) combination. Cell cycle analysis revealed that carvedilol (10 microM) significantly decreased the number of cells in S and G2/M phases. These results indicate that carvedilol inhibits the exaggerated proliferation of pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension partially via its beta-blocking [corrected] and calcium channel blocking effects in vitro.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16495763     DOI: 10.1097/01.fjc.0000201359.58174.c8

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

Review 1.  Treatment of pulmonary arterial hypertension in children.

Authors:  Heiner Latus; Tammo Delhaas; Dietmar Schranz; Christian Apitz
Journal:  Nat Rev Cardiol       Date:  2015-02-03       Impact factor: 32.419

Review 2.  Neurohormonal activation and pharmacological inhibition in pulmonary arterial hypertension and related right ventricular failure.

Authors:  Pietro Ameri; Edoardo Bertero; Giovanni Meliota; Martino Cheli; Marco Canepa; Claudio Brunelli; Manrico Balbi
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

Review 3.  Epoprostenol sodium for treatment of pulmonary arterial hypertension.

Authors:  Yukihiro Saito; Kazufumi Nakamura; Satoshi Akagi; Toshihiro Sarashina; Kentaro Ejiri; Aya Miura; Aiko Ogawa; Hiromi Matsubara; Hiroshi Ito
Journal:  Vasc Health Risk Manag       Date:  2015-05-14

Review 4.  Nanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension.

Authors:  Kazufumi Nakamura; Hiromi Matsubara; Satoshi Akagi; Toshihiro Sarashina; Kentaro Ejiri; Norifumi Kawakita; Masashi Yoshida; Toru Miyoshi; Atsuyuki Watanabe; Nobuhiro Nishii; Hiroshi Ito
Journal:  J Clin Med       Date:  2017-04-29       Impact factor: 4.241

Review 5.  Current Treatment Strategies and Nanoparticle-Mediated Drug Delivery Systems for Pulmonary Arterial Hypertension.

Authors:  Kazufumi Nakamura; Satoshi Akagi; Kentaro Ejiri; Masashi Yoshida; Toru Miyoshi; Norihisa Toh; Koji Nakagawa; Yoichi Takaya; Hiromi Matsubara; Hiroshi Ito
Journal:  Int J Mol Sci       Date:  2019-11-23       Impact factor: 5.923

6.  Imatinib dramatically alleviates pulmonary tumour thrombotic microangiopathy induced by gastric cancer.

Authors:  Kana Kubota; Taro Shinozaki; Yasushi Imai; Kazuomi Kario
Journal:  BMJ Case Rep       Date:  2017-09-07

7.  Crucial role of RAGE in inappropriate increase of smooth muscle cells from patients with pulmonary arterial hypertension.

Authors:  Kazufumi Nakamura; Masakiyo Sakaguchi; Hiromi Matsubara; Satoshi Akagi; Toshihiro Sarashina; Kentaro Ejiri; Kaoru Akazawa; Megumi Kondo; Koji Nakagawa; Masashi Yoshida; Toru Miyoshi; Takeshi Ogo; Takahiro Oto; Shinichi Toyooka; Yuichiro Higashimoto; Kei Fukami; Hiroshi Ito
Journal:  PLoS One       Date:  2018-09-04       Impact factor: 3.240

Review 8.  Neurohormonal modulation in pulmonary arterial hypertension.

Authors:  Eva L Peters; Harm Jan Bogaard; Anton Vonk Noordegraaf; Frances S de Man
Journal:  Eur Respir J       Date:  2021-10-28       Impact factor: 16.671

9.  Carvedilol targets β-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy.

Authors:  Joseph I Hoare; Bleona Osmani; Emily A O'Sullivan; Ashley Browne; Nicola Campbell; Stephen Metcalf; Francesco Nicolini; Jayeta Saxena; Sarah A Martin; Michelle Lockley
Journal:  Commun Biol       Date:  2022-02-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.